Table 2.
Blood levels of PCDDs/PCDFs/Co-PCBs (in pg/g lipid and pg TEQ/g lipid) and total TEQ of participants (N = 490) in SEDOCCH 2011–2016
| Frequencies of values below the LOD, n (%)* | 25th percentile | Median | 75th percentile | 95th percentile | |
|---|---|---|---|---|---|
| PCDDs (pg/g lipid) | |||||
| 2,3,7,8-TeCDD | 378 (77.1) | <LOD | <LOD | <LOD | 2. 0 (2.0–2.0) |
| 1,2,3,7,8-PeCDD | 51 (10.4) | 2.0 (2.0–2.0) | 3.0 (3.0–3.0) | 4.0 (4.0–4.0) | 7.0 (6.0–8.0) |
| 1,2,3,4,7,8-HxCDD | 442 (90.2) | <LOD | <LOD | <LOD | 3.0 (2.0–3.0) |
| 1,2,3,6,7,8-HxCDD | 15 (3.0) | 5.0 (5.0–5.0) | 8.0 (8.0–9.0) | 12.2 (12.0–14.0) | 23.0 (20.0–25.0) |
| 1,2,3,7,8,9-HxCDD | 345 (70.4) | <LOD | <LOD | 2.0 (2.0–2.0) | 4.0 (4.0–5.0) |
| 1,2,3,4,6,7,8-HpCDD | 3 (0.6) | 5.5 (5.0–6.0) | 7.0 (7.0–7.1) | 10.0 (9.0–10.0) | 17.0 (15.0–19.9) |
| OCDD | 0 (0.0) | 67.0 (64.0–70.0) | 96.0 (91.0–100.0) | 130.0 (130.0–150.0) | 284.5 (241.2–320.0) |
| Total PCDDs (pg/g lipid) | – | 82.0 (79.0–86.0) | 120.0 (110.0–120.0) | 160.0 (150.0–180.0) | 320.0 (290.0–359.9) |
| Total PCDDs (pg TEQ/g lipid) | – | 2.5 (2.4–2.6) | 3.8 (3.6–4.0) | 5.9 (5.3–6.2) | 11.2 (9.9–12.7) |
| PCDFs (pg/g lipid) | |||||
| 2,3,7,8-TeCDF | 366 (74.6) | <LOD | <LOD | <LOD | 2.0 (2.0–2.0) |
| 1,2,3,7,8-PeCDF | 398 (81.2) | <LOD | <LOD | <LOD | 2.0 (1.0–2.0) |
| 2,3,4,7,8-PeCDF | 9 (1.8) | 4.0 (4.0–4.0) | 5.0 (5.0–5.0) | 7.0 (7.0–7.5) | 12.0 (11.0–13.9) |
| 1,2,3,4,7,8-HxCDF | 325 (66.3) | <LOD | < LOD | 2.0 (2.0–2.0) | 4.0 (3.0–5.0) |
| 1,2,3,6,7,8-HxCDF | 229 (46.7) | <LOD | 2.0(<LOD–2.0) | 3.0 (3.0–3.0) | 5.0 (5.0–6.0) |
| 1,2,3,7,8,9-HxCDF | 490 (100.0) | <LOD | <LOD | <LOD | <LOD |
| 2,3,4,6,7,8-HxCDF | 460 (93.8) | <LOD | <LOD | <LOD | 2.0 (<LOD–2.0) |
| 1,2,3,4,6,7,8-HpCDF | 374 (76.3) | <LOD | <LOD | <LOD | 4.0 (3.0–5.0) |
| 1,2,3,4,7,8,9-HpCDF | 490 (100.0) | <LOD | <LOD | <LOD | <LOD |
| OCDF | 490 (100.0) | <LOD | <LOD | <LOD | <LOD |
| Total PCDFs (pg/g lipid) | – | 4.0 (4.0–4.0) | 8.0 (7.0–9.0) | 13.0 (12.0–14.0) | 26.0 (23.1–30.0) |
| Total PCDFs (pg TEQ/g lipid) | – | 1.2 (1.2–1.2) | 1.8 (1.7–1.9) | 2.6 (2.4–2.8) | 4.7 (4.2–5.3) |
| Total (PCDDs+PCDFs) (pg/g lipid) | – | 89.0 (85.0–96.0) | 130.0 (120.0–131.9) | 172.5 (160.0–190.0) | 334.5 (300.0–379.9) |
| Total (PCDDs+PCDFs) (pg TEQ/g lipid) | – | 3.8 (3.6–4.0) | 5.7 (5.3–6.0) | 8.3 (7.7–8.9) | 16.0 (14.0–18.0) |
| Co-PCBs (non-ortho PCBs and mono-ortho PCBs) | |||||
| Non-ortho PCBs (pg/g lipid) | |||||
| 3,3′,4,4’-TeCB (#77) | 489 (99.8) | < LOD | < LOD | < LOD | < LOD |
| 3,4,4′,5-TeCB (#81) | 490 (100.0) | < LOD | < LOD | < LOD | < LOD |
| 3,3′,4,4′,5-PeCB (#126) | 56 (11.4) | 20.0 (10.0–20.0) | 20.0 (20.0–30.0) | 40.0 (40.0–50.0) | 90.0 (80.0–100.0) |
| 3,3′,4,4′,5,5’-HxCB (#169) | 28 (5.7) | 20.0 (20.0–20.0) | 25.0 (20.0–30.0) | 40.0 (30.0–40.0) | 74.5 (70.0–90.0) |
| Total non-ortho PCBs (pg/g lipid) | – | 30.0 (30.0–40.0) | 50.0 (50.0–50.0) | 80.0 (70.0–90.0) | 164.5 (141.2–180.0) |
| Total non-ortho PCBs (pg TEQ/g lipid) | – | 2.1 (1.6–2.6) | 3.2 (2.9–3.6) | 5.2 (4.8–5.9) | 11.4 (10.2–12.7) |
| 2,3,3′,4,4’-PeCB (#105) | 0 (0.0) | 600.0 (544.3–650.0) | 940.0 (890.0–1000.0) | 1600.0 (1400.0–1756.2) | 3400.0 (2900.0–3899.2) |
| Mono-ortho PCBs (pg/g lipid) | |||||
| 2,3,4,4′,5-PeCB (#114) | 0 (0.0) | 180.0 (160.0–190.0) | 290.0 (250.0–320.0) | 480.0 (440.0–530.0) | 1000.0 (881.2–1100.0) |
| 2,3′,4,4′,5-PeCB (#118) | 0 (0.0) | 3175.0 (2900.0–3500.0) | 5200.0 (4800.0–5600.0) | 8400.0 (7800.0–9400.0) | 18,000.0 (16,000.0–20,000.0) |
| 2′,3,4,4′,5-PeCB (#123) | 2 (0.4) | 50.0 (40.0–50.0) | 70.0 (70.0–80.0) | 130.0 (120.0–140.0) | 284.5 (231.2–349.9) |
| 2,3,3′,4,4′,5-HxCB (#156) | 0 (0.0) | 1300.0 (1200.0–1400.0) | 2100.0 (1980.4–2300.0) | 3300.0 (3000.0–3600.0) | 7045.0 (5912.0–8398.4) |
| 2,3,3′,4,4′,5’-HxCB (#157) | 0 (0.0) | 350.0 (330.0–380.0) | 570.0 (530.0–610.0) | 880.0 (800.0–970.0) | 1900.0 (1600.0–2200.0) |
| 2,3′,4,4′,5,5’-HxCB (#167) | 0 (0.0) | 530.0 (480.0–570.0) | 850.0 (790.0–940.0) | 1300.0 (1200.0–1500.0) | 3045.0 (2612.5–3300.0) |
| 2,3,3′,4,4′,5,5’-HpCB (#189) | 0 (0.0) | 177.5 (160.0–190.0) | 270.0 (250.0–290.0) | 412.5 (390.0–450.0) | 984.5 (833.7–1199.6) |
| Total mono-ortho PCBs (pg/g lipid) | – | 6800.0 (6200.0–7200.0) | 10,500.0 (9600.0–11,000.0) | 16,250.0 (15,000.0–18,000.0) | 34,450.0 (31,000.0–38,996.2) |
| Total mono-ortho PCBs (pg TEQ/g lipid) | – | 0.2 (0.2–0.2) | 0.3 (0.3–0.3) | 0.5 (0.5–0.5) | 1.0 (0.9–1.2) |
| Total Co-PCBs (pg/g lipid) | – | 6800.0 (6200.0–7200.0) | 11,000.0 (9700.0–12,000.0) | 17,000.0 (15,000.0–18,000.0) | 34,450.0 (31,124.9–38,996.2) |
| Total Co-PCBs (pg TEQ/g lipid) | – | 2.4 (1.8–2.8) | 3.6 (3.2–3.9) | 5.7 (5.2–6.6) | 12.0 (11.0–14.0) |
| Total (PCDDs + PCDFs + Co-PCBs) (pg/g lipid) | – | 6915.0 (6267.1–7326.4) | 11,057.0 (9848.7–11,857.8) | 17,066.0 (15,202.8–18,191.6) | 35,187.4 (31,280.6–39,107.0) |
| Total (PCDDs + PCDFs + Co-PCBs) (pg TEQ/g lipid) | – | 6.1 (5.5–6.6) | 9.4 (8.8–9.9) | 14.0 (13.0–9.9) | 27.5 (24.0–31.0) |
95% confidence intervals are presented in parentheses
SEDOCCH survey on the exposure to dioxins and other chemical compounds in humans, PCDDs polychlorinated dibenzo-dioxins, PCDFs polychlorinated dibenzofurans, Co-PCBs coplanar polychlorinated biphenyls, LOD limit of detection
*A value of zero was assigned to concentrations below the LOD